Major β blocker mortality trials in chronic heart failure: a critical review
Key result
This critical review of major beta-blocker trials in chronic heart failure notes that CIBIS II and MERIT-HF share similar designs and outcomes, while differing significantly from the USCP.
Why the study?
Does beta blocker treatment reduce mortality in patients with chronic heart failure caused by left ventricular systolic dysfunction?
Population
Patients with chronic heart failure (CHF) caused by left ventricular systolic dysfunction
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
May guide beta-blocker selection in systolic HF; leaves open reconciliation of USCP differences with current evidence.
Structured PICO
Does beta blocker treatment reduce mortality in patients with chronic heart failure caused by left ventricular systolic dysfunction?
P
Population
Patients with chronic heart failure (CHF) caused by left ventricular systolic dysfunction
I
Intervention
Beta adrenoceptor antagonist (beta blocker) treatment (specifically carvedilol, bisoprolol, and metoprolol CR/XL)
O
Outcome
Mortalityhard clinical
This review compares the design and outcomes of three major beta-blocker mortality trials (USCP, CIBIS II, MERIT-HF) in chronic heart failure to draw conclusions for routine clinical practice.
Limitations
- Comparison of the USCP and the other two trials is difficult due to differences in design, including a prerandomisation open label run-in period and shorter follow up in the USCP.
Cite This Study
John J.V. McMurray (1999) conducted a review in Chronic heart failure (CHF) caused by left ventricular systolic dysfunction. β adrenoceptor antagonist (β blocker) was evaluated on Mortality. This critical review of major beta-blocker trials in chronic heart failure notes that CIBIS II and MERIT-HF share similar designs and outcomes, while differing significantly from the USCP.